Scalable Manufacturing of Engineered Treg cells for Vein-to-Vein Processes

Time: 12:00 pm
day: Day Two | Track A | Morning


• Maintaining function while consistently producing disease-specific Treg cells
• Providing stability and viability while freezing to allow for adequate storing and timely administration
• Assessing stability of phenotype profiles to prevent T cell reversion and ensure safety when transplanting back into the patient